Recurrence rate of basal cell carcinoma after topical aminolevulinic acid-based photodynamic therapy

Acta Dermatovenerologica Croatica

Volumn 12, Issue 3, 2004, Pages 157-161

  Naidenov, Nickolai ^a   Denchevo, Rositsa ^a   Tsankov, Nikolay ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Basal cell carcinoma; Phototherapy; Recurrence

Indexed keywords

AMINOLEVULINIC ACID;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DRUG STRUCTURE; ESTHETICS; FEMALE; FOLLOW UP; HUMAN; LIGHT; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; RECURRENCE RISK; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 8744248963     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Fitzpatrick TB, Pathak MA, Historical aspects of methoxsalen and other furocoumarins. J Invest Dermatol 1059;23:229-31.
2. Daniel MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991;61:340-8.
3. Warloe T, Peng Q, Heyerdahl J, Moan J, Steen B, Giercksky KE. Photodynamic therapy with 5-aminolevulinic acid induced porphyrins and DMSO/EDTA for basal cell carcinoma. Proc SPIE 1995;2371:226-35.
4. Von Tappeiner H, Jodibauer A. Über die Wirkung der photodinamischen (fluorescierenden) Stoffe auf Protozoan und Enzyme. Dtsch Arch Klin Med 1904;80: 427-87.
5. Szeimies RM, Sassy T, Landthaler M. Penetration potency of topical applied-aminolevulinicacid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol 1994;59:73-6.
6. Petkov II, Boyanov L, Tsankov N. Photodynamic inactivation of herpes simplex virus. Dermatol Venerol 1974;3:148-51.
7. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38: 2628-35.
8. Bissonnette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin 1997;15:507-19.
9. Lui H, Anderson RR. Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993;11: 1-13.
10. Peng Q, Warloe T, Berg C, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997;79:2282-308.
11. Keller GS, Razum NJ, Doiron DR. Photodynamic therapy for non-melanoma skin cancer. Facial Plast Surg 1989;6:180-4.
12. Pennington DG, Waner M, Knox A. Photodynamic therapy for multiple skin cancers. Plast Reconstr Surg 1988;82:1067-71.
13. Roberts DJ, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg 1995;48: 360-70.
14. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992; 128: 1597-601.
15. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 1998;134:821-6.
16. Langmack K, Metha R, Twyman P, Norris P. Topical photodynamic therapy at low fluency rates - theory and practice. J Photochem Photobiol B. 2001;60: 37-43.
17. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: result of a phase III trial. Br J Dermatol 2001;144:832-40.
18. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolevulinicacidasan appropriate approach to the routine treatment of superficial nonmelanoma skin tumors. J Photochem Photobiol B 1995;29:53-7.
19. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
20. Orenstein A, Kostenich G, Tsur H, Roitman L, Ehrenberg B, Malik Z. Photodynamic therapy of human skin tumors using topical application of 5-aminolevulinic acid, DMSO and EDTA. Proc SPIE 1995;2325:100-5.
21. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993;28:17-21.
22. Fijan S, Hönigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumors using delta-aminole-vulinicacid and desferrioxamine. Br J Dermatol 1995; 133:282-8.
23. Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995; 287:665-74.
24. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248-9.
25. Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51.
26. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906-13.
27. Haller JC, Cairnduff F, Slack G, Schofield J, Whitehurst C, Tunstall R, et al. Routine treatments of superficial basal cell carcinomas using aminolevulinic acid-based photodynamic therapy. Br J Dermatol 2000;143:1270-4.
28. Ortel B, Tanew A, Hönigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cells: modification by desferrioxamine. J Photochem Photobiol B 1993;17:273-8.
29. Peng Q, Moan J, Iani V, Nesland JM. Effect of desferrioxamine on production of ALA-induced protoporphyrin IX in normal mouse skin. Proc SPIE 1996;2625:51-7.
30. Malik Z, Kostenich G, RoitmEn L, Ehrenberg B, Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumors of mice. J Photochem Photobiol B 1995;28:213-8.
31. Rowe DE, Carrol RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28.